open access

Vol 73, No 3 (2022)
Review paper
Submitted: 2022-04-24
Accepted: 2022-04-24
Early publication date: 2022-05-21
Get Citation

Therapy of obesity in women with PCOS using GLP-1 analogues — benefits and limitations [Terapia otyłości u kobiet z PCOS przy zastosowaniu analogów GLP-1 — korzyści i ograniczenia]

Agnieszka Baranowska-Bik1
DOI: 10.5603/EP.a2022.0047
·
Endokrynol Pol 2022;73(3):627-643.
Affiliations
  1. Department of Endocrinology, Centre of Postgraduate Medical Education; Bielański Hospital, Warsaw, Poland

open access

Vol 73, No 3 (2022)
Review Article
Submitted: 2022-04-24
Accepted: 2022-04-24
Early publication date: 2022-05-21

Abstract

Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder among women of reproductive age. The incidence ranges from approx. 6% to 20%. PCOS is characterized by a spectrum of symptoms and clinical features that includes ovarian dysfunction, clinical and/or biochemical hyperandrogenism, and ultrasound evidence of morphologically polycystic ovaries. Obesity is present in 40–70% of patients with the syndrome. Adiposity is involved in exacerbating the negative effects of insulin resistance, hyperinsulinaemia, and hyperandrogenaemia in the course of PCOS. Therefore, it is essential to maintain normal weight or effectively treat overweight/obesity in patients suffering from this endocrinopathy. Apart from diet and lifestyle interventions, an appropriate pharmacological or surgical treatment should be selected for the individual patient. Evidence-based data have unequivocally proven the validity of the use of glucagon-like peptide 1 (GLP-1) analogues in the treatment of overweight/obese patients with PCOS. The result of the GLP-1 therapy is not only a reduction of body weight but also an improvement in insulin resistance and a decrease in hyperandrogenaemia. It also seems that this treatment method increases spontaneous and in-vitro pregnancy rates. Therefore, the GLP-1 treatment of obese PCOS women is a new therapeutic opportunity not only for weight loss but also for a wide range of benefits.

This review summarizes and discusses findings regarding obesity and its relation to hyperandrogenism and insulin resistance in PCOS, with special attention paid to the pharmacological treatment of adiposity with GLP-1 analogues.

Abstract

Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder among women of reproductive age. The incidence ranges from approx. 6% to 20%. PCOS is characterized by a spectrum of symptoms and clinical features that includes ovarian dysfunction, clinical and/or biochemical hyperandrogenism, and ultrasound evidence of morphologically polycystic ovaries. Obesity is present in 40–70% of patients with the syndrome. Adiposity is involved in exacerbating the negative effects of insulin resistance, hyperinsulinaemia, and hyperandrogenaemia in the course of PCOS. Therefore, it is essential to maintain normal weight or effectively treat overweight/obesity in patients suffering from this endocrinopathy. Apart from diet and lifestyle interventions, an appropriate pharmacological or surgical treatment should be selected for the individual patient. Evidence-based data have unequivocally proven the validity of the use of glucagon-like peptide 1 (GLP-1) analogues in the treatment of overweight/obese patients with PCOS. The result of the GLP-1 therapy is not only a reduction of body weight but also an improvement in insulin resistance and a decrease in hyperandrogenaemia. It also seems that this treatment method increases spontaneous and in-vitro pregnancy rates. Therefore, the GLP-1 treatment of obese PCOS women is a new therapeutic opportunity not only for weight loss but also for a wide range of benefits.

This review summarizes and discusses findings regarding obesity and its relation to hyperandrogenism and insulin resistance in PCOS, with special attention paid to the pharmacological treatment of adiposity with GLP-1 analogues.

Get Citation

Keywords

PCOS; obesity; insulin resistance; androgens; GLP-1 analogue

About this article
Title

Therapy of obesity in women with PCOS using GLP-1 analogues — benefits and limitations [Terapia otyłości u kobiet z PCOS przy zastosowaniu analogów GLP-1 — korzyści i ograniczenia]

Journal

Endokrynologia Polska

Issue

Vol 73, No 3 (2022)

Article type

Review paper

Pages

627-643

Early publication date

2022-05-21

Page views

609

Article views/downloads

132

DOI

10.5603/EP.a2022.0047

Bibliographic record

Endokrynol Pol 2022;73(3):627-643.

Keywords

PCOS
obesity
insulin resistance
androgens
GLP-1 analogue

Authors

Agnieszka Baranowska-Bik

References (57)
  1. Rodriguez-Pacheco F, Martinez-Fuentes AJ, Tovar S, et al. Regulation of pituitary cell function by adiponectin. Endocrinology. 2007; 148(1): 401–410.
  2. Yildiz BO, Bozdag G, Yapici Z, et al. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012; 27(10): 3067–3073.
  3. Sanchez-Garrido MA, Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab. 2020; 35: 100937.
  4. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19(1): 41–47.
  5. Palomba S. Is fertility reduced in ovulatory women with polycystic ovary syndrome? An opinion paper. Hum Reprod. 2021; 36(9): 2421–2428.
  6. Sadeghi HM, Adeli I, Calina D, et al. Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing. Int J Mol Sci. 2022; 23(2).
  7. Parker J, O'Brien C, Hawrelak J, et al. Polycystic Ovary Syndrome: An Evolutionary Adaptation to Lifestyle and the Environment. Int J Environ Res Public Health. 2022; 19(3).
  8. Livadas S, Anagnostis P, Bosdou JK, et al. Polycystic ovary syndrome and type 2 diabetes mellitus: A state-of-the-art review. World J Diabetes. 2022; 13(1): 5–26.
  9. Zeng X, Xie YJ, Liu YT, et al. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020; 502: 214–221.
  10. Rana MN, Neeland IJ. Adipose Tissue Inflammation and Cardiovascular Disease: An Update. Curr Diab Rep. 2022; 22(1): 27–37.
  11. Li Y, Chen C, Ma Y, et al. Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS). Life Sci. 2019; 228: 167–175.
  12. Dewailly D, Barbotin AL, Dumont A, et al. Role of Anti-Müllerian Hormone in the Pathogenesis of Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). 2020; 11: 641.
  13. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016; 37(5): 467–520.
  14. Ye W, Xie T, Song Y, et al. The role of androgen and its related signals in PCOS. J Cell Mol Med. 2021; 25(4): 1825–1837.
  15. Baskind NE, Balen AH. Hypothalamic-pituitary, ovarian and adrenal contributions to polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2016; 37: 80–97.
  16. Greenwood EA, Huddleston HG. Insulin resistance in polycystic ovary syndrome: concept versus cutoff. Fertil Steril. 2019; 112(5): 827–828.
  17. Ibáñez L, Oberfield SE, Witchel S, et al. An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence. Horm Res Paediatr. 2017; 88(6): 371–395.
  18. Shang Y, Zhou H, Hu M, et al. Effect of Diet on Insulin Resistance in Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2020; 105(10).
  19. Cassar S, Misso ML, Hopkins WG, et al. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod. 2016; 31(11): 2619–2631.
  20. Svendsen PF, Nilas L, Nørgaard K, et al. Obesity, body composition and metabolic disturbances in polycystic ovary syndrome. Hum Reprod. 2008; 23(9): 2113–2121.
  21. Kempegowda P, Melson E, Manolopoulos KN, et al. Implicating androgen excess in propagating metabolic disease in polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2020; 11: 2042018820934319.
  22. Barber TM, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf). 2021; 95(4): 531–541.
  23. Barber TM, Golding SJ, Alvey C, et al. Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008; 93(3): 999–1004.
  24. Cena H, Chiovato L, Nappi RE. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. J Clin Endocrinol Metab. 2020; 105(8).
  25. de Medeiros SF, Rodgers RJ, Norman RJ. Adipocyte and steroidogenic cell cross-talk in polycystic ovary syndrome. Hum Reprod Update. 2021; 27(4): 771–796.
  26. Lin K, Sun X, Wang X, et al. Circulating Adipokine Levels in Nonobese Women With Polycystic Ovary Syndrome and in Nonobese Control Women: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2020; 11: 537809.
  27. Toulis KA, Goulis DG, Farmakiotis D, et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update. 2009; 15(3): 297–307.
  28. Delitala AP, Capobianco G, Delitala G, et al. Polycystic ovary syndrome, adipose tissue and metabolic syndrome. Arch Gynecol Obstet. 2017; 296(3): 405–419.
  29. Mancini A, Bruno C, Vergani E, et al. Oxidative Stress and Low-Grade Inflammation in Polycystic Ovary Syndrome: Controversies and New Insights. Int J Mol Sci. 2021; 22(4).
  30. Allen LA, Shrikrishnapalasuriyar N, Rees DA. Long-term health outcomes in young women with polycystic ovary syndrome: A narrative review. Clin Endocrinol (Oxf). 2021 [Epub ahead of print].
  31. Sam S, Tasali E. Role of obstructive sleep apnea in metabolic risk in PCOS. Curr Opin Endocr Metab Res. 2021; 17: 46–51.
  32. Cooney LG, Dokras A. Cardiometabolic Risk in Polycystic Ovary Syndrome: Current Guidelines. Endocrinol Metab Clin North Am. 2021; 50(1): 83–95.
  33. Kim CH, Lee SH. Effectiveness of Lifestyle Modification in Polycystic Ovary Syndrome Patients with Obesity: A Systematic Review and Meta-Analysis. Life (Basel). 2022; 12(2).
  34. Bjekić-Macut J, Vukašin T, Velija-Ašimi Z, et al. Polycystic Ovary Syndrome: A Contemporary Clinical Approach. Curr Pharm Des. 2021; 27(36): 3812–3820.
  35. Rashid R, Mir SA, Kareem O, et al. Polycystic ovarian syndrome-current pharmacotherapy and clinical implications. Taiwan J Obstet Gynecol. 2022; 61(1): 40–50.
  36. Abdalla MA, Deshmukh H, Atkin S, et al. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2020; 11: 2042018820938305.
  37. Xu Y, Wu Y, Huang Q. Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis. Arch Gynecol Obstet. 2017; 296(4): 661–677.
  38. Abdalla MA, Shah N, Deshmukh H, et al. Impact of pharmacological interventions on anthropometric indices in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. Clin Endocrinol (Oxf). 2021 [Epub ahead of print].
  39. Wang F, Zhang ZF, He YR, et al. Effects of dipeptidyl peptidase-4 inhibitors on transforming growth factor-β1 signal transduction pathways in the ovarian fibrosis of polycystic ovary syndrome rats. J Obstet Gynaecol Res. 2019; 45(3): 600–608.
  40. Javed Z, Papageorgiou M, Deshmukh H, et al. Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study. Clin Endocrinol (Oxf). 2019; 90(6): 805–813.
  41. Ahmed MI, Duleba AJ, El Shahat O, et al. Naltrexone treatment in clomiphene resistant women with polycystic ovary syndrome. Hum Reprod. 2008; 23(11): 2564–2569.
  42. Yaribeygi H, Sathyapalan T, Sahebkar A. Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity. Life Sci. 2019; 234: 116776.
  43. Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022; 57: 101351.
  44. Hazlehurst JM, Singh P, Bhogal G, et al. How to manage weight loss in women with obesity and PCOS seeking fertility? Clin Endocrinol (Oxf). 2022 [Epub ahead of print].
  45. Holst JJ. From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy. Front Endocrinol (Lausanne). 2019; 10: 260.
  46. Zhao X, Wang M, Wen Z, et al. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front Endocrinol (Lausanne). 2021; 12: 721135.
  47. Jensterle M, Janez A, Fliers E, et al. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Hum Reprod Update. 2019; 25(4): 504–517.
  48. Salamun V, Jensterle M, Janez A, et al. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol. 2018; 179(1): 1–11.
  49. Niafar M, Pourafkari L, Porhomayon J, et al. A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries. Arch Gynecol Obstet. 2016; 293(3): 509–515.
  50. Han Yi, Li Y, He B. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reprod Biomed Online. 2019; 39(2): 332–342.
  51. Lyu X, Lyu T, Wang X, et al. The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight /Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Int J Endocrinol. 2021; 2021: 6616693.
  52. Ma R, Ding X, Wang Y, et al. The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021; 100(23): e26295.
  53. Tao X, Zhang X, Ge S, et al. Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide. Int J Clin Exp Pathol. 2015;8(7).; 8(7): 8276–8283.
  54. Piltonen TT. Polycystic ovary syndrome: Endometrial markers. Best Pract Res Clin Obstet Gynaecol. 2016; 37: 66–79.
  55. Artunc-Ulkumen B, Pala HG, Pala EE, et al. Exenatide improves ovarian and endometrial injury and preserves ovarian reserve in streptozocin induced diabetic rats. Gynecol Endocrinol. 2015; 31(3): 196–201.
  56. Nylander M, Frøssing S, Clausen HV, et al. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online. 2017; 35(1): 121–127.
  57. Liu X, Zhang Y, Zheng SY, et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. Clin Endocrinol (Oxf). 2017; 87(6): 767–774.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl